drugset / Trial / NCT02308202
DOXAZOSIN FOR PTSD
RandomizedCrossoverDouble-blindTreatment
Summary
The aims of this study is to determine the effects of treatment with doxazosin XL 16 mg/d combined with virtual reality (VR) exposure therapy on Post Traumatic Stress Disorder. The effects of treatment with doxazosin XL 16 mg/d combined with virtual reality (VR) exposure therapy will be assessed in double-blind, placebo-controlled study. The study will enroll 30 participants. The investigators will use a within groups design in which all participants receive both placebo and doxazosin (N=16) with the order counterbalanced across participants. A second group of patients (N=16) will receive both 16mg perindopril and placebo instead of doxazosin/placebo.
Timeline
- Start
- 2012-01
- Primary completion
- 2014-06-30
- Completion
- 2014-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Doxazosin | Small molecule | 16 mg | — |
| Comparator | Perindopril | Small molecule | 16 mg | — |